Therefore, anti-TNF biologics and/or adiponectin analogs or medications that increase endogenous adiponectin may be investigated combined with ICIs in the treatment of NAFLD-associated HCC. Here, TNF is linked to metabolic dysfunction-associated steatotic liver disease.